Dietary supplement targeting neuropathic pain via seh inhibition
A novel dietary supplement targets neuropathic pain by inhibiting the enzyme soluble epoxide hydrolase (sEH), preventing degradation of endogenous analgesic lipids. This approach offers potential as an over-the-counter nutraceutical for enhancing resilience to pain with fewer side effects.
Overview
This dietary supplement is innovatively designed to address neuropathic pain by targeting the enzyme soluble epoxide hydrolase (sEH). The supplement is hypothesized to prevent the degradation of endogenous analgesic lipids, providing an analgesic effect. Unlike current nonsteroidal anti-inflammatory drugs (NSAIDs), this approach is anticipated to offer pain relief without the associated side effects, making it a promising candidate for over-the-counter medication or as a nutraceutical enhancing resilience to pain.
Technical specifications
Key features:
- Targets sEH to prevent degradation of analgesic lipids
- Composed of alkaloids that are non-addictive, non-psychoactive, and non-toxic
- Potential to support resilience against both inflammatory and neuropathic pain
The dietary supplement leverages the inhibition of sEH, a strategy validated through animal models and early-stage clinical trials of a similar drug candidate. The supplement's formulation includes alkaloids known for their anti-inflammatory properties, offering a safer alternative to existing pain management solutions.
Technology readiness level
This technology is currently at a Technology Readiness Level 3. It has demonstrated its potential through initial research and animal model testing. Further validation, including trials in animal models and human clinical trials, is necessary to optimize its formulation and confirm its efficacy and safety profile.
About Vanderbilt University
Vanderbilt University is a private, research‑intensive university in Nashville that combines residential undergraduate education with advanced graduate and professional training. Industry engages through co‑located core labs and prototyping spaces, an on‑campus innovation center, and streamlined pathways for sponsored research and clinical studies with its closely affiliated medical center. Nashville’s concentration of healthcare companies and a growing tech and advanced manufacturing base provide a strong regional partner network and access to real‑world testbeds. Research is supported by competitive federal funding, including major awards from NIH, NSF, DOE, and DoD. A dedicated technology transfer office manages IP, licensing, and startups.
delivered to your inbox.